5,825 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Bought by Bleakley Financial Group LLC

Bleakley Financial Group LLC purchased a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 5,825 shares of the company's stock, valued at approximately $323,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its position in shares of Tarsus Pharmaceuticals by 16.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company's stock worth $6,924,000 after purchasing an additional 29,465 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Tarsus Pharmaceuticals by 2,088.8% in the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company's stock valued at $14,477,000 after buying an additional 420,057 shares during the last quarter. Creative Planning bought a new stake in Tarsus Pharmaceuticals in the third quarter valued at about $362,000. Vestal Point Capital LP bought a new stake in Tarsus Pharmaceuticals in the third quarter valued at about $7,565,000. Finally, Jennison Associates LLC increased its holdings in Tarsus Pharmaceuticals by 14.8% in the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock valued at $138,432,000 after buying an additional 321,552 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.

Analyst Ratings Changes

TARS has been the subject of several research analyst reports. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. Barclays boosted their price objective on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an "overweight" rating in a report on Monday, January 27th. The Goldman Sachs Group boosted their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a report on Friday, November 15th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Tarsus Pharmaceuticals in a report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $56.00.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ:TARS traded down $2.01 during trading on Friday, hitting $50.22. 315,387 shares of the company traded hands, compared to its average volume of 545,759. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of -13.18 and a beta of 1.01. The business's fifty day moving average is $52.07 and its 200-day moving average is $41.68. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.